30 research outputs found
Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, stratified by hormonal receptor status, E3N cohort (<i>n = </i>88,387).
<p>Women with missing information on hormone receptor status were excluded from this analysis (<i>n = </i>1,415).</p>b<p>Adjusted for age (timescale), education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories (Model 2).</p>c<p>Additionally adjusted for personal history of BBD and family history of breast cancer (model used for homogeneity test) (Model 4).</p
Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, stratified by hormonal receptor status, E3N cohort (<i>n = </i>88,387).
<p>Women with missing information on hormone receptor status were excluded from this analysis (<i>n = </i>1,415).</p>b<p>Adjusted for age (timescale), education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories (Model 2).</p>c<p>Additionally adjusted for personal history of BBD and family history of breast cancer (model used for homogeneity test) (Model 4).</p
Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, stratified by menopausal status, E3N cohort (<i>n = </i>89,802).
a<p>Adjusted for age (timescale), education, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories (Model 2).</p>b<p>Additionally adjusted for personal history of BBD and family history of breast cancer (model used for homogeneity test) (Model 4).</p
Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, stratified by histological type of breast cancer, E3N cohort (<i>n</i> = 89,429).
a<p>Adjusted for age (timescale), education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories (Model 2).</p>b<p>Additionally adjusted for personal history of BBD and family history of breast cancer (model used for homogeneity test) (Model 4).</p
Odds ratios and 95% confidence intervals for number of nevi in relation to family history of breast cancer, E3N cohort.
a<p>Adjusted for education and age at inclusion.</p
Hazard ratios and 95% confidence intervals for risk of breast cancer in relation to number of nevi, E3N cohort (<i>n = </i>89,802).
a<p>Adjusted for age (timescale), education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), and use of premenopausal progestogens, and stratified according to year of birth in 5-y categories.</p>b<p>Model 2 additionally adjusted for personal history of BBD.</p>c<p>Model 3 additionally adjusted for personal history of BBD and family history of breast cancer.</p>d<p>Model 4 additionally adjusted for BMI, height, physical activity, age at menarche, age at first full-term pregnancy, parity, breastfeeding, use of OCs, history of mammographic exam, UV dose in county of birth, and UV dose in county of residence at inclusion.</p
Odds ratios and 95% confidence intervals for number of nevi in relation to history of benign breast disease, E3N cohort.
a<p>Adjusted for age at cohort inclusion, age at last returned questionnaire, education, menopausal status, age at menopause (in postmenopausal women), use of MHT (in postmenopausal women), use of premenopausal progestogens, and family history of breast cancer.</p
Association between menstrual and reproductive factors and breast cancer risk.
<p>Association between menstrual and reproductive factors and breast cancer risk.</p
Baseline characteristics of case and control subjects [number (percentage) or mean ± standard deviation].
<p>Baseline characteristics of case and control subjects [number (percentage) or mean ± standard deviation].</p
Additional file 4: of Mitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study
Table S4. Associations between mtDNA integrity (ND4/ND1 divided by ND1/nuclear genome) and BC risk. (DOCX 15 kb